Scientific Sessions 2024  /  Applying Advances in Risk Prediction to PREVENT CV Disease  /  Using risk prediction to guide the use of non-statin pharmacotherapies
Logo

American Heart Association

  2
  0

Final ID:

Using risk prediction to guide the use of non-statin pharmacotherapies

  • Pandey, Ambarish  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Berg, David  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
    • Author Disclosures:
    Ambarish Pandey: DO have relevant financial relationships ; Consultant:Tricog:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Semler:Active (exists now) ; Consultant:Science37:Active (exists now) ; Research Funding (PI or named investigator):SCPharma:Active (exists now) ; Advisor:Medtronic:Active (exists now) ; Advisor:Axon:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Research Funding (PI or named investigator):Ultromics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Roche:Active (exists now) | David Berg: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Applying Advances in Risk Prediction to PREVENT CV Disease

Monday, 11/18/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
The nuts and bolt of the PREVENT risk model

Khan Sadiya, Coresh Josef

External validation of PREVENT in a large health system

Go Alan

More abstracts from these authors:
Neo’s Quest: Leveraging informatics to achieve GDMT for heart failure

Pandey Ambarish, Desai Akshay

The Intertwined Epidemics of Obesity and HFpEF: Implications for the Future of HF

Pandey Ambarish, Tsao Connie

You have to be authorized to contact abstract author. Please, Login
Not Available